- Home
- MRK vs JNJ Comparison
MRK vs JNJ Comparison
Compare MRK & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRK | JNJ |
|---|---|---|
| Founded | 2000 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.8B | 542.4B |
| IPO Year | 1995 | 2003 |
Fundamental Metrics
Financial Performance| Metric | MRK | JNJ |
|---|---|---|
| Price | $153.15 | $269.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 20 |
| Target Price | $125.59 | ★ $238.20 |
| AVG Volume (30 Days) | ★ 5.8M | 5.2M |
| Earning Date | 04-30-2026 | 04-14-2026 |
| Dividend Yield | ★ 3.06% | 2.36% |
| EPS Growth | 8.01 | ★ 90.50 |
| EPS | N/A | ★ 4.41 |
| Revenue | ★ $65,011,000,000.00 | N/A |
| Revenue This Year | $3.61 | $6.63 |
| Revenue Next Year | $5.41 | $7.43 |
| P/E Ratio | ★ N/A | $61.10 |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $77.58 | $175.74 |
| 52 Week High | $157.00 | $281.07 |
Technical Indicators
Market Signals| Indicator | MRK | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 47.78 |
| Support Level | $145.75 | $262.26 |
| Resistance Level | $152.80 | $269.43 |
| Average True Range (ATR) | 2.63 | 4.71 |
| MACD | -0.72 | -0.70 |
| Stochastic Oscillator | 57.63 | 26.32 |
Price Performance
Historical ComparisonAbout MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.